Depressive Disorder, Major
Conditions
Brief summary
To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.
Interventions
None listed
Sponsors
i3 Innovus
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥1 fill for an augmentation therapy medication from Table 1 during the identification period of 01 January 2005 - 30 November 2008. * 12 months of continuous enrollment with medical and pharmacy benefits each before the index date (pre-index period) and after the index date (post-index period). * ≥1 medical claim with a primary International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis for MDD (296.2x, 296.3x, 311.xx) during the pre-index period. * Age ≥18 years as of the year of the pre-index period.
Exclusion criteria
* No pharmacy claims for atypical antipsychotics, mood stabilizers, anxiolytics, anticonvulsants, or stimulants, during the pre-index period. * No medical claims with primary or secondary diagnoses for non-MDD episodic mood disorders or schizophrenia during the pre-index or post-index periods.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All cause health care costs | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Health care resource utilization: All cause, MDD related, mental health related | 12 months |
| Duration of index therapies | 12 months |
| Health care costs: MDD related, mental health related | 12 months |
| Discontinuation of index therapies | 12 months |
| Therapy switches to a non-index antidepressant or non-index augmentation therapy | 12 months |
| Medication possession ratio to evaluate adherence | 12 months |
Outcome results
None listed